HHS Peptide Compounding Policy: What 503A Pharmacies Need From Their API Supplier

On October 30, 2026, the US Department of Health and Human Services (HHS) published a notice in the Federal Register announcing an interim enforcement discretion policy for 503A compounding with six peptide bulk drug substances: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. Under the policy, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound with these peptides, provided they meet the policy's conditions. Several of those conditions apply to the bulk active pharmaceutical ingredient (API) itself, so pharmacies now need to know exactly what to ask their peptide supplier.

This article summarizes what the policy covers, what it does not do, and the documentation a compounding pharmacy should request before buying peptide APIs. It is not legal advice; always check the current policy text on the HHS website.

Key Takeaways

• The policy covers six peptides, each in a specified salt form and dosage route.
• It is enforcement discretion, not approval. HHS states that compounded drugs are not FDA-approved, and none of the six peptides has been added to the 503A bulks list.
• The API must be made by an FDA-registered establishment (Section 510 of the FD&C Act) that complies with Current Good Manufacturing Practice (CGMP), and must come with a valid certificate of analysis (COA).
• Each compounded product may contain only one of the listed peptides and must be made for a valid, patient-specific prescription.
• The policy is interim: it applies while FDA develops the 503A bulks list through rulemaking, and HHS may revisit it if a safety signal or quality issue arises.

Which Peptides Does the HHS Policy Cover?

As summarized by the law firm BakerHostetler from the HHS policy, the six peptides, salt forms and permitted dosage forms are:

Peptide	Form covered	Permitted dosage forms
BPC-157	Acetate	Subcutaneous, intramuscular, oral and topical
TB-500	Acetate	Subcutaneous or intramuscular injectable
Epitalon	Acetate	Subcutaneous or intramuscular injectable, dispensed in intermittent courses
Semax	Free base	Intranasal
KPV	Acetate	Topical and oral
MOTS-c	Acetate	Subcutaneous or intramuscular injectable

The salt form matters. A COA for the free base does not document the acetate, and the reverse is also true, so order the exact form the policy names for your intended route.

What the Policy Does Not Do

• It does not make these peptides FDA-approved drugs. In the Federal Register notice, HHS states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before they are marketed.
• It does not add them to the 503A bulks list. HHS says FDA's future rulemakings "may propose" adding some or all of the peptides based on the available evidence.
• It is not permanent or binding. The notice says the policy does not establish any rights and is not binding on HHS or the public, and that HHS may revisit it if a safety signal or product quality issue arises.

Conditions That Apply to the Peptide API

The policy sets conditions for compounders. The ones that depend directly on the bulk drug substance and your supplier are:

1. FDA-registered manufacturer. The bulk substance must be manufactured by an establishment registered with FDA under Section 510 of the FD&C Act.
2. CGMP compliance. The original manufacturer must comply with Current Good Manufacturing Practice requirements.
3. Valid certificate of analysis. Each lot must come with a COA that includes testing consistent with the criteria referenced in the policy.

Other conditions apply to the compounded product: a valid patient-specific prescription, a single listed peptide per product, compounding by a licensed pharmacist or physician, the label statement "This is a compounded drug product. Not for resale.", documentation of adequate bioavailability for oral forms, FDA-cleared syringes as the only co-packaged device, reporting of serious adverse events and quality issues to FDA MedWatch and state authorities, and compliance with all other Section 503A requirements.

How to Qualify a Peptide API Supplier: A Checklist

1. Identify the original manufacturer. Ask for the manufacturer's name and site address, not just the distributor's.
2. Verify FDA establishment registration. Confirm the site's registration under Section 510 and keep the evidence in your supplier file.
3. Request CGMP evidence, such as recent inspection history or audit reports for the manufacturing site.
4. Get a lot-specific COA for the exact salt form, and check that its tests match the criteria in the HHS policy.
5. Confirm the peptide sequence and identity on the COA, along with purity and impurity results.
6. Keep traceability: lot numbers, shipping records and storage conditions from manufacturer to pharmacy.
7. Re-check the policy before each order. It is interim and can change.

Sourcing peptide APIs for 503A compounding? Request a quote, tell us which peptide and salt form you need, and we'll confirm the manufacturer and the documentation available for each lot.

Peptides in the Parchem Catalog

Parchem lists BPC-157, Epitalon, Semax and MOTS-C. Availability of a specific salt form, and of a source that meets the policy's manufacturer and COA conditions, must be confirmed lot by lot before purchase.

Frequently Asked Questions

Is BPC-157 FDA-Approved Now?

No. The HHS policy is enforcement discretion for 503A compounding. HHS states that compounded drugs are not FDA-approved, and BPC-157 has not been added to the 503A bulks list.

When Did the HHS Peptide Policy Take Effect?

The notice of availability was published in the Federal Register on October 30, 2026 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). Written comments could be submitted for two weeks after publication.

Can a Compounded Product Combine BPC-157 and TB-500?

Not under this policy. Each compounded product may contain only a single active ingredient from the list.

What Documentation Should a Peptide API Come With?

At minimum, a lot-specific certificate of analysis with testing consistent with the policy's criteria, plus evidence that the original manufacturer is FDA-registered under Section 510 and complies with CGMP.

Does the Policy Apply to Outsourcing Facilities (503B)?

The notice addresses compounding under section 503A by state-licensed pharmacies, federal facilities and licensed physicians. Check the policy text for anything beyond that scope.

Sources

• US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, FR Doc. 2026-22192, October 30, 2026.
• HHS, 503A peptide enforcement discretion policy (current version).
• BakerHostetler. HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (2026).
• Header image: Peptide synthesizer by Michael Pereckas, CC BY-SA 2.0, via Wikimedia Commons.